Albert David Ltd Stock Price Today (NSE: ALBERTDAVD)
Fundamental Score
Albert David Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Albert David Ltd share price today is ₹707.10, down 1.08% on NSE/BSE as of 17 June 2026. Albert David Ltd (ALBERTDAVD) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹444.56 (Cr). The 52-week high for ALBERTDAVD share price is ₹957.50 and the 52-week low is ₹579.90. The company has a Return on Equity (ROE) of 4.39% and a debt-to-equity ratio of 0.11.
Albert David Ltd Share Price Chart — NSE/BSE Historical Performance
Albert David Ltd share price chart: 0.28% return over the past month. 52-week high ₹957.50, 52-week low ₹579.90.
Albert David Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹708.25 | ₹721.65 | ₹704.10 | ₹715.45 | 2.25K (Cr) | |
| ₹710.10 | ₹723.00 | ₹705.00 | ₹706.40 | 1.68K (Cr) | |
| ₹717.10 | ₹720.00 | ₹705.00 | ₹708.45 | 2.08K (Cr) | |
| ₹714.95 | ₹720.65 | ₹709.95 | ₹716.10 | 4.78K (Cr) | |
| ₹712.10 | ₹730.90 | ₹708.55 | ₹714.45 | 2.28K (Cr) | |
| ₹705.80 | ₹727.95 | ₹705.80 | ₹722.80 | 1.14K (Cr) | |
| ₹714.65 | ₹715.00 | ₹704.90 | ₹705.80 | 5.46K (Cr) | |
| ₹715.20 | ₹715.50 | ₹704.50 | ₹706.30 | 1.24K (Cr) | |
| ₹707.20 | ₹711.65 | ₹704.85 | ₹708.35 | 734.00 (Cr) | |
| ₹708.95 | ₹719.20 | ₹708.95 | ₹716.45 | 1.15K (Cr) |
Albert David Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹710.10 | ₹723.00 | ₹704.10 | ₹715.45 | +0.75% | |
| ₹700.65 | ₹819.60 | ₹700.65 | ₹708.45 | +1.11% | |
| ₹605.00 | ₹769.80 | ₹602.15 | ₹715.40 | +18.25% | |
| ₹695.30 | ₹710.20 | ₹579.90 | ₹587.05 | -15.57% | |
| ₹696.65 | ₹779.00 | ₹678.30 | ₹711.55 | +2.14% | |
| ₹738.20 | ₹769.00 | ₹663.35 | ₹687.40 | -6.88% | |
| ₹790.00 | ₹801.35 | ₹731.00 | ₹736.60 | -6.76% | |
| ₹840.00 | ₹903.00 | ₹776.30 | ₹792.90 | -5.61% | |
| ₹785.80 | ₹866.45 | ₹775.00 | ₹849.90 | +8.16% | |
| ₹801.40 | ₹820.00 | ₹771.40 | ₹781.25 | -2.51% | |
| ₹896.15 | ₹915.05 | ₹788.40 | ₹801.40 | -10.57% | |
| ₹835.10 | ₹957.50 | ₹835.10 | ₹891.05 | +6.70% |
AI Research Briefing
Powered by Gemini · 2026-04-22
A micro-cap 'hope' story with weak fundamentals and high liquidity risk; avoid until earnings show a clear turnaround.
WHAT'S HAPPENING NOW
No major catalysts found after live search. The company announced closure of its trading window from April 1, 2026, until 48 hours after the declaration of audited financial results. They also re-lodged transfer of 300 physical equity shares.
CORE STORY
Albert David is a micro-cap pharma company trading on hopes of a turnaround, but struggling with profitability and growth.
- India Pharma 2026 highlights policy push
- Low Debt/Equity at 0.11
- Significant order wins
- Successful launch of new products
- Turnaround in profitability
- Micro/SME cap implies liquidity risk
- Negative Profit CAGR 5Y: -2.13%
- Negative Interest Coverage: -9.33x
FII decreased stake by 0.24% [cite: brief]
Indian pharma sector has tailwinds, but Albert David's execution is questionable
Free Cash Flow 5Y: ₹64.39 Cr [cite: brief] - Profit not consistently converting to cash
3-6 month thesis hinges on earnings turnaround. Without it, expect further downside. Monitor Q4 results closely.
Primary Thesis Risk
Failure to achieve earnings turnaround will lead to significant downside.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Albert David Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Albert David Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ALBERTDAVD across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Conservative Debt Levels (D/E: 0.11)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Cash Generation (₹64.39 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (62.24%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (4.39%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.45%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-118.26%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-11.38%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (1.52% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-2.13% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-2.13% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-9.33x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 2.25%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Albert David Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Albert David Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Albert David LtdAlbert David Lt...Selected✓ ALBERTDAVD • 524075 | 18.6/100 | ₹707.10₹707 | ₹444.56₹444.56 | — — | 4.39%Poor 4.39% Poor | 6.45%Poor 6.45% Poor | 0.11Excellent 0.1 Excellent | -2.13%Poor -2.13% Poor | 1.52%Average 1.52% Average | 0.64% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Albert David Ltd PE Ratio History
Historical price-to-earnings ratio for ALBERTDAVD — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹30.14 | ₹736.60 | 24.4x |
| FY 2024 | ₹132.15 | ₹1327.10 | 10x |
| FY 2023 | ₹63.39 | ₹975.35 | 15.4x |
| FY 2022 | ₹61.78 | ₹566.75 | 9.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Albert David Ltd Dividend History
Annual cash dividends paid by ALBERTDAVD — dividend yield 0.64%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹6.55 Cr |
| FY 2024 | ₹5.17 Cr |
| FY 2023 | ₹5.15 Cr |
| FY 2022 | ₹3.44 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Albert David Ltd Quarterly Performance
Latest quarterly metrics for ALBERTDAVD — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-11.38%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-118.26%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
1.52%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-2.13%
Compounded annual net profit growth over 5 years
Albert David Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ALBERTDAVD — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Albert David Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Albert David Ltd (ALBERTDAVD) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Albert David Ltd
About ALBERTDAVD (Albert David Ltd)
Albert David Ltd is a venerable pharmaceutical company with deep roots in the Indian healthcare landscape. Established in 1938, the Kolkata-based organization has cultivated a stro...ng reputation as a manufacturer and distributor of a diverse range of pharmaceutical products, catering to both domestic and international markets. Their portfolio spans a broad spectrum of therapeutic areas, showcasing a commitment to addressing a wide array of medical needs. From essential formulations to specialized treatments, Albert David Ltd strives to provide accessible and reliable healthcare solutions. This dedication to quality and patient well-being has solidified their position as a trusted partner for healthcare professionals and consumers alike. The company's product offerings encompass a variety of dosage forms, reflecting a sophisticated understanding of drug delivery systems and patient preferences. They are known for their expertise in manufacturing parenterals, ensuring the availability of critical medications for intravenous administration. Additionally, they provide oral and enteral formulations, offering convenient and effective treatment options for various conditions. Furthermore, Albert David Ltd extends its capabilities to topical agents, aerosol products, and specialized therapies, including products for gynecology, orthopedics, and vision care. This comprehensive approach demonstrates their commitment to innovation and meeting the evolving needs of the healthcare industry. Beyond conventional pharmaceuticals, Albert David Ltd also explores the potential of herbal medicine, developing herbal dosage forms that leverage the therapeutic properties of natural ingredients. This reflects a forward-thinking approach, embracing both modern science and traditional knowledge to create holistic healthcare solutions. Coupled with their focus on manufacturing bulk drugs, Albert David Ltd demonstrates a vertically integrated approach, ensuring control over the quality and supply chain of their products. Through their unwavering commitment to research, development, and manufacturing excellence, Albert David Ltd continues to play a significant role in shaping the future of healthcare.
Company Details
Key Leadership
Corporate Events
ALBERTDAVD Share Price: Frequently Asked Questions
What is the current share price of Albert David Ltd?
Albert David Ltd (ALBERTDAVD) trades at ₹707.10 on NSE and BSE. Market cap ₹444.56 (Cr). Educational data only.
What is the P/E ratio of Albert David Ltd?
Albert David Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Albert David Ltd?
Albert David Ltd has a Bull Run score of 18.6/100 based on 25+ financial parameters.
Does Albert David Ltd pay dividends?
Albert David Ltd has a dividend yield of 0.64%. Past dividends don't guarantee future payments.
What is the ROE of Albert David Ltd?
Albert David Ltd has ROE of 4.39%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Albert David Ltd?
Albert David Ltd has debt-to-equity of 0.11.
Is Albert David Ltd a good investment?
Bull Run gives Albert David Ltd a score of 18.6/100. This is not investment advice — consult a SEBI-registered advisor.